Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg

NACompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

March 1, 2021

Study Completion Date

March 31, 2021

Conditions
Bioequivalence
Interventions
DRUG

Orlistat 60mg Cap

Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.

Trial Locations (1)

276006

Shaohong Yin, Linyi

All Listed Sponsors
lead

Shandong New Time Pharmaceutical Co., LTD

INDUSTRY

NCT05076474 - Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg | Biotech Hunter | Biotech Hunter